A complete response letter (CRL) from the FDA delays a product's entry to the market by an average of 14 months. Companies that receive the letters take an average of seven months just to respond to them. Imagine how much you could save if you could anticipate the FDA's concerns and address them before the agency issues the complete response letter? Now you can.
A review of several corrective and preventive action (CAPA) forms at Aqueduct Medical’s San Francisco facility revealed inadequate CAPA validation and follow-up, a recent Form 483 states. Aqueduct, a maker of masks and vests for use by patients during recovery from facial and cosmetic surgery, opened several CAPAs in 2010 and 2011 to address defective welds but did not document any follow-up with its contract manufacturers, the Dec. 7, 2011, form states. The GMP Letter